Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Aethlon Medical to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Volatility and Risk

Aethlon Medical has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Aethlon Medical’s rivals have a beta of 1.20, suggesting that their average share price is 20% more volatile than the S&P 500.

Profitability

This table compares Aethlon Medical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aethlon Medical N/A -126.58% -96.36%
Aethlon Medical Competitors -190.83% -33.65% -15.46%

Valuation & Earnings

This table compares Aethlon Medical and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aethlon Medical $150,000.00 -$5.67 million -2.21
Aethlon Medical Competitors $1.08 billion $109.59 million 24.66

Aethlon Medical’s rivals have higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aethlon Medical and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aethlon Medical 0 0 1 0 3.00
Aethlon Medical Competitors 120 743 1096 53 2.54

Aethlon Medical presently has a consensus target price of $3.00, suggesting a potential upside of 195.04%. As a group, “Analytical instruments” companies have a potential upside of 4.79%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, research analysts plainly believe Aethlon Medical is more favorable than its rivals.

Insider & Institutional Ownership

7.4% of Aethlon Medical shares are owned by institutional investors. Comparatively, 62.9% of shares of all “Analytical instruments” companies are owned by institutional investors. 6.6% of Aethlon Medical shares are owned by company insiders. Comparatively, 14.7% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Aethlon Medical rivals beat Aethlon Medical on 8 of the 13 factors compared.

Aethlon Medical Company Profile

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.